On track to meet full-year earnings guidance based on strong ConfirmMDx growth
Jean-Marc Roelandt appointed Chief Financial Officer
IRVINE, CA, and HERSTAL, BELGIUM – January 9, 2017 – MDxHealth SA (Euronext: MDXH.BR) today provides a preliminary update on its year-end results, reporting that it expects to achieve its upgraded market guidance for full-year 2016 financial results following continued strong growth of ConfirmMDx® and early adoption of SelectMDx(TM) for Prostate Cancer during the year.
The Company previously upgraded its expected full-year revenue growth to more than 60% compared with its initial guidance predicting growth of 30-50% over 2015. Underlying Earnings Before Interest, Taxes, Depreciation and Amortization (EBIDTA) are also expected to improve compared to 2015.
Full-year 2016 results will reflect initial sales of the Company’s SelectMDx for Prostate Cancer “liquid biopsy” test. Since commercial launch of SelectMDx, more than 3,000 patients have been tested and 11 U.S. insurance companies have agreed to cover the test. The Company has also signed 7 distribution agreements for SelectMDx, covering regions in Europe, Israel, Latin America and Asia.
“In 2016 we experienced a significant increase in payor adoption of ConfirmMDx, with 19 new payor agreements and 28 commercial and Medicare Advantage payors issuing positive medical policy, following the test’s inclusion in the US National Comprehensive Cancer Network (NCCN) Clinical Guidelines earlier this year,” reported Dr. Jan Groen, Chief Executive Officer of MDxHealth. “This translated into a sharp revenue increase for the year, which we plan to build upon in 2017.”
MDxHealth plans to announce its full-year 2016 results on February 23, 2017.
Separately, MDxHealth announces the appointment of Jean-Marc Roelandt as Chief Financial Officer with effect from January 15, 2017.
Mr. Roelandt joins MDxHealth after having served as Chief Financial Officer and Managing Director at BHF Kleinwort Benson (previously known as RHJ International) since 2006. In addition to his responsibilities as a member of BHF Kleinwort Benson Group’s executive management, he was also appointed Executive Director and Chief Financial Officer of Kleinwort Benson Bank in London from July 2015 until the acquisition of the BHF Kleinwort Benson Group by Oddo & Cie in 2016.
Mr. Roelandt began his professional career as an audit manager at Ernst & Young and qualified as a certified public accountant (Instituut van de Bedrijfsrevisoren) in 1996, after which he held various senior positions in several publicly-listed Belgian companies, including Chief Financial Officer of Ubizen NV. He holds a master’s degree in Applied Economic Sciences from the University of Ghent, Belgium.
“We are delighted to welcome Jean-Marc Roelandt to the executive management team as Chief Financial Officer,” commented Dr. Groen. “Jean-Marc’s extensive business and financial experience will be invaluable as we continue the successful commercialization of our innovative diagnostic products in the U.S., Europe and other key markets around the world.”
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic and epigenetic (methylation) molecular technologies and assist physicians with the diagnosis of urological cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
| For more information:
Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70
Jonathan Birt, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.